Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc, dated August 19, 2026, reports on the completion of a share buyback programme. Haleon is a consumer health company focused on categories including Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health.
Key Financial Metrics and Capital Actions
The filing details specific share repurchase transactions rather than operational financial results such as revenue or profit.
- Buyback Completion: The Company completed its £500 million share buyback programme announced on March 12, 2026.
- Recent Transactions: On August 17 and 18, 2026, the Company purchased 1,569,800 ordinary shares for cancellation across the London Stock Exchange, CBOE (UK)/BXE, CBOE (UK)/CXE, and Aquis.
- YTD Repurchases: Since the start of 2026, the Company has repurchased 144,012,239 shares, all of which were cancelled.
- Share Capital: Following settlement, registered share capital is 8,808,341,409 ordinary shares of £0.01 each, with 11,807,443 held as treasury shares.
- Voting Rights: The number of ordinary shares with voting rights is 8,796,533,966.
- Transaction Prices: The volume-weighted average price paid per share ranged from approximately 351.89p to 352.75p during the reported dates.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
The primary material change is the reduction in the number of outstanding shares due to the cancellation of 144,012,239 shares repurchased year-to-date. The filing does not disclose material changes to operational performance compared to prior periods.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future outlook, or discussion of specific risks and contingencies beyond standard regulatory disclosures regarding the Market Abuse Regulation and the non-offer nature of the announcement.
Investor Verification Checklist
- Verify the total cost of the £500 million buyback programme against the number of shares repurchased to confirm the average cost basis.
- Confirm the updated share count (8,796,533,966 voting shares) for calculating earnings per share (EPS) and ownership thresholds.
- Review the full trade breakdown available via the provided London Stock Exchange link for granular transaction data.
- Check subsequent filings for the impact of the share cancellation on the Company's balance sheet and cash position.